Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme

BMC Cancer

Table 4 Multivariate analysis of MGMT promoter methylation and its association with the overall survival of GBM patients

Variable	Haz. ratio	p-value	[95% Conf. Interval]
Sex
male	1.488	0.238	0.769	2.876
(ref. female)	1.259	0.602	0.530	2.992
(ref. female)	1.724	0.393	0.494	6.024
Age
50- <60 years	1.734	0.299	0.613	4.903
(ref. <50 years)	1.648	0.394	0.523	5.192
(ref. <50 years)	1.183	0.916	0.053	26.577
Age
60- <70 years	2.567	0.057	0.972	6.780
(ref. <50 years)	3.242	0.039	1.061	9.901
(ref. <50 years)	1.417	0.757	0.156	12.826
Age
≥70 years	6.427	0.001	2.194	18.824
(ref. <50 years)	10.700	0.000	2.998	38.191
(ref. <50 years)	2.442	0.445	0.247	24.152
Mean methylation	0.988	0.315	0.964	1.012
level (continuous)	0.975	0.121	0.945	1.007
	1.023	0.403	0.970	1.078

Continuous multivariate Cox model regression analysis of MGMT promoter methylation and its association with the overall survival (OS) of the analyzed patients with glioblastoma multiforme, adjusted for potential risk factors including sex and age at diagnosis and stratified on the variable therapy. Normal typed data: the entire glioblastoma cohort; Italic data: Temozolomide treated glioblastoma patients; Bold face data: Glioblastoma patients without temozolomide treatment (Haz. Ratio, Hazard Ratio; Conf. Interval, Confidence Interval).

ISSN: 1471-2407